* Transcript of the earnings conference call for the quarter and half year ended September 30, 2025, has been released. * The conference call was conducted after the Board of Directors meeting held on November 12, 2025. * Vivek Sharma shared his perspective on the quarter, highlighting the company's transition from integration to capability amplification. * The company is moving towards its U.S. $1 billion (₹8,336 crore) vision. * One of the late-phase molecules in the respiratory inflammatory segment received U.S. regulatory approval. * The company's senior team met with over 340 customers at CPHI in Frankfurt. * Demand from large innovative customers remains positive. * Yann D'Herve discussed the pharma CDMO performance. * One of the late-stage molecules received U.S. regulatory approval during the quarter. * Gunjan Singh discussed the API Plus business, including FDF operations. * The API site at Jaggaiahpet cleared the U.S. FDA audit with zero observations. * Himanshu Agarwal discussed the financial highlights for Q2 and the first half of FY26 and revised FY26 guidance. * FY26 revenue is expected to be broadly flattish versus FY25. * H2 is expected to be stronger than H1, driven by execution of deferred shipments, new program activations, and regulatory normalization in key sites. * The company maintains its mid-term guidance of U.S. $1 billion (₹8,336 crore) with mid-30s EBITDA margin.
